Back to top
more

IDEXX Laboratories (IDXX)

(Delayed Data from NSDQ)

$472.35 USD

472.35
432,975

+3.17 (0.68%)

Updated Sep 6, 2024 04:00 PM ET

After-Market: $470.94 -1.41 (-0.30%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 28% (70 out of 249)

Industry: Medical - Instruments

Better trading starts here.

Zacks News

Masimo (MASI) Launches Trace Data and Reporting Tool in US

Masimo's (MASI) launch of Trace in the United States will aid the company in capturing the growing patient data visualization market.

    Genomic Health's Cost Pressure Mounts, Cancer Tests Strong

    Concerns related to Genomic Health's (GHDX) strong dependence on breast cancer tests still linger. Also, higher production cost and expenses continue to weigh heavily on the company's margins.

      Integra Rides High on Product Launches, Competition Rife

      Integra LifeSciences' (IART) latest launch of new sizes of SurgiMend and PriMatrix and Omnigraft as well as continued growth in private label products is encouraging.

        Henry Schein to Offer CAS' Fully-Automated Cognivue Device

        Henry Schein (HSIC) is consistently working toward boosting its Medical segment.

          Hill-Rom (HRC) Rides on Product Launches, Competition Rife

          Hill-Rom (HRC) focuses on product innovation through research and development. Its product launches slated for the fourth quarter are boosting investors' confidence.

            Integra LifeSciences' SurgiMend PRS Meshed Boosts ADM Line

            Advancing its portfolio of acellular dermal tissue matrix for plastic and reconstructive surgery, including breast reconstruction, Integra LifeSciences (IART) launched SurgiMend PRS Meshed in Europe.

              AmerisourceBergen's PharMEDium Slows Down, Competition Rife

              AmerisourceBergen'S (ABC) growth story is expected to be stunted by tepid performance at PharMEDium. Also steep competition is a cause of concern.

                AngioDynamicis' (ANGO) Solero MTA System to Drive Growth

                Growth in the core Angiographic Catheter business is also likely to fortify the company's footprint in the global space.

                  Integra Closes Codman Buyout, Strengthens Neurosurgery Arm

                  With Codman's acquisition by Integra (IART), the neurosurgery business is likely to drive the company's 2018 adjusted earnings per share with a minimum yield of 22 cents.

                    Amedisys' Arm Buys Intercity Home Care, Boosts U.S. Base

                    Amedisys' (AMED) encouraging efforts put the Personal Care business on growth track. This segment lives up to a strong performance with the integration of several recent tuck-in acquisitions.

                      Boston Scientific's Apama Deal to Boost Electrophysiology Arm

                      Boston Scientific's (BSX) Apama Medical addition is expected to strengthen its suite of arrhythmia solutions under the Electrophysiology sub-segment.

                        Quest Diagnostics Buys 2 Outreach Labs, Widens Customer Base

                        Quest Diagnostics (DGX) completes acquisition of outreach laboratory services of two Hartford HealthCare hospitals. The deal is expected to widen the network of the company.

                          Abbott to Gain from Alere's Takeover Due for Oct 3 Closure

                          Alere's acquisition would help Abbott (ABT) explore new channels and geographies, including forays into fast growing outlets like doctors' offices, clinics, pharmacies and at-home testing.

                            AngioDynamics (ANGO) Misses on Earnings & Revenues in Q1

                            AngioDynamics' (ANGO) adjusted gross margin decreased year over year owing to voluntary market withdrawal of the Acculis Microwave Tissue Ablation System.

                              Masimo RAS-45 Full-Market Release to Boost Respiratory Care

                              Masimo Corporation's (MASI) newly launched RAS-45, a single use adhesive respiration sensor would strengthen the company's foothold in the growing global respiratory care market.

                                Baxter Announces Launch of DeviceVue System for Sigma Pumps

                                Baxter's (BAX) latest development is expected to fortify its foothold in the smart pumps market.

                                  Here's Why Mazor Robotics (MZOR) Stock Is Worth a Bet Now

                                  The market is upbeat about Mazor Robotics' (MZOR) recent CE Mark approval for Mazor X Surgical Assurance platform.

                                    STERIS (STE) Rides on Organic Growth, Stiff Contest a Threat

                                    STERIS' (STE) consistent strong organic all-segment growth performance impresses investors. Additionally, growth in free cash flow reserve denotes the company's solid cash position.

                                      Here's Why You Should Invest in Orthofix International Now

                                      Orthofix (OFIX) rides high on strength in Biologics and Spine Fixation.

                                        Allscripts Rides High on Product Launches Amid Rising Costs

                                        Management at Allscripts Healthcare (MDRX) is focused on various restructuring initiatives, research and development plans and launch of exclusive products.

                                          Omnicell (OMCL) Gains on Product Launches, Global Expansion

                                          The market is upbeat about Omnicell's (OMCL) recently-launched XT Series Automated Supply Dispensing Cabinet. The company is also expanding its footprint globally.

                                            Align Technology (ALGN) Prospects Bright, Competition Rife

                                            Align Technology (ALGN) continues to gain from strong InvisAlign sales amid macroeconomic headwinds.

                                              Cerner (CERN) Banks on RCM & PH Platforms, Competition Rife

                                              Cerner's (CERN) stable position provides solid growth opportunities in the revenue cycle management (RCM) suite of solutions.

                                                PetMed Express Optimistic on New Orders Amid Stiff Rivalry

                                                PetMed is striving to implement several strategies to revitalize its top line. Yet a highly competitive market poses threats.

                                                  Here's Why Investors Should Buy Masimo (MASI) Right Now

                                                  Masimo (MASI) announced 510(k) clearance and full-market release of its proprietary Rad-97 Pulse CO-Oximeter earlier this month.